As NOTCH1 activation increased STING1 expression and STING pathway sensitivity, we next hypothesized that STING agonism may augment in vivo antitumor immune responses in Notch-driven SCLC tumors. This evidence concerns the gene NOTCH1 and small cell lung carcinoma.